Alluvi, known as BI 4744, presents a significant development in obesity treatment. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable efficacy in https://fellowfavorite.com/story23559674/alluvi-a-in-depth-dive-into-the-drug-s-prospects